Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
177.5 SEK | -0.45% | -0.22% | -8.83% |
May. 02 | Vitrolife to Acquire Dutch Company eFertility | MT |
May. 02 | Vitrolife AB (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for ?18 million. | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company is in a robust financial situation considering its net cash and margin position.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an expected P/E ratio at 45.57 and 35.71 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.83% | 2.23B | B- | ||
-3.58% | 12.64B | B+ | ||
-1.48% | 8.46B | B- | ||
+8.70% | 5.66B | B | ||
+24.28% | 5.27B | C | ||
-4.58% | 4.49B | C | ||
-51.45% | 3.11B | D+ | ||
+16.25% | 2.87B | - | - | |
+30.98% | 2.31B | C | ||
-4.08% | 1.89B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VITR Stock
- Ratings Vitrolife AB